Search research articles
Contact Us
Filters
Showing results (21-30 of 85) with videos related to
Page
of 9
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 10, 2011
A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma
Valerie P Grignol, Thomas Olencki, Kiran Relekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2010
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma
Brian I Rini, Jorge A Garcia, Matthew M Cooney, et al.
Pediatric Blood & Cancer
|
August 20, 2013
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group
Brenda Weigel, Suman Malempati, Joel M Reid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2008
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b
James C Yao, Alexandria Phan, Paulo M Hoff, et al.
The Oncologist
|
June 10, 2015
The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab
Naifa L Busaidy, Patricia LoRusso, Kristie Lawhorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2008
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer
Tanguy Y Seiwert, Daniel J Haraf, Ezra E W Cohen, et al.
Investigational New Drugs
|
October 17, 2014
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma
Jennifer J Knox, Rui Qin, Jonathan R Strosberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2006
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients
Bhuvaneswari Ramaswamy, Anthony D Elias, Nicole T Kelbick, et al.
Chinese Journal of Cancer
|
November 25, 2014
Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting
Feng Roger Luo, Jian Ding, Helen X Chen, et al.
Annals of Surgical Oncology
|
May 31, 2007
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma
Kimberly A Varker, Jennifer E Biber, Cheryl Kefauver, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 85) with videos related to
Sort By:
Page
of 9
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 10, 2011
A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma
Valerie P Grignol, Thomas Olencki, Kiran Relekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2010
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma
Brian I Rini, Jorge A Garcia, Matthew M Cooney, et al.
Pediatric Blood & Cancer
|
August 20, 2013
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group
Brenda Weigel, Suman Malempati, Joel M Reid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2008
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b
James C Yao, Alexandria Phan, Paulo M Hoff, et al.
The Oncologist
|
June 10, 2015
The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab
Naifa L Busaidy, Patricia LoRusso, Kristie Lawhorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2008
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer
Tanguy Y Seiwert, Daniel J Haraf, Ezra E W Cohen, et al.
Investigational New Drugs
|
October 17, 2014
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma
Jennifer J Knox, Rui Qin, Jonathan R Strosberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2006
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients
Bhuvaneswari Ramaswamy, Anthony D Elias, Nicole T Kelbick, et al.
Chinese Journal of Cancer
|
November 25, 2014
Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting
Feng Roger Luo, Jian Ding, Helen X Chen, et al.
Annals of Surgical Oncology
|
May 31, 2007
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma
Kimberly A Varker, Jennifer E Biber, Cheryl Kefauver, et al.
Page
of 9